Announcement PDF Completion of Consolidation of Capital MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 12 June 2026: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, advises that the consolidation of the Company’s issued capital on a fifty (50) to one (1) basis, as approved by shareholders at the General Meeting on 29 May 2026, has now been completed. The Company’s post-consolidation capital structure is as follows: ASX CODE QUOTED SECURITIES NUMBER ATH Ordinary fully paid shares 217,508,862 ATHO Option expiring 31-Aug-2026 ex $0.50 18,624,729 ATHOA Option expiring 26-Feb-2027 ex $1.40 24,446,043 ASX CODE UNQUOTED SECURITIES NUMBER ATHAA Option expiring 13-Mar-2029 ex $0.20 403,334 ATHAAE Option expiring 29-Nov-2026 ex $1.875 200,000 ATHAAG Option expiring 29-Nov-2026 ex $1.19 230,000 ATHAAH Option expiring 19-Dec-2026 ex $0.525 160,000 ATHAAK Option expiring 30-Dec-2027 ex $0.50 3,400,000 ATHAAL Option expiring 09-Jan-2031 ex $0.40 360,000 ATHAAM Option expiring 13-Jan-2031 ex USD 0.285 870,000 ATHAB Option expiring 13-Mar-2029 ex USD 0.155 1,250,000 ATHAC Option expiring 21-Mar-2029 ex USD 0.15 800,004 ATHAD Option expiring 01-Jul-2030 ex $0.50 300,000 ATHAE Option expiring 08-Aug-2030 ex $0.65 230,000 ATHAF Option expiring 08-Aug-2030 ex USD 0.43 6,248,004 ATHAG Option expiring 26-Mar-2031 ex USD 0.285 1,230,000 ATHAJ Option expiring 15-Apr-2031 ex USD 0.302 4,245,000 ATHAK Option expiring 15-Apr-2031 ex $0.45 540,000 Where the consolidation process resulted in a fraction of a share, any fractional entitlements have been rounded up to the nearest whole number (to a minimum of 1 security). Holding statements have been despatched to all shareholders and option holders advising them of their holdings on a post-consolidation basis. Normal trading (on a T+2 settlement basis) commenced today, Friday 12 June, under ASX code “ATH”. Authorised for release by the Board of Directors of Alterity Therapeutics Limited. About Alterity Therapeutics Limited Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at www.alteritytx.com. Contacts: Investors Elyse Shapiro ir@alteritytx.com Remy Bernarda Investor Relations Advisory Solutions ir@alteritytx.com +1 (415) 203-6386 Media Casey McDonald Tiberend Strategic Advisors, Inc. cmcdonald@tiberend.com +1 (646) 577-8520